Literature DB >> 33115273

Genome-Wide Association Study Highlights APOH as a Novel Locus for Lipoprotein(a) Levels-Brief Report.

George Thanassoulis1,2, James C Engert1,3,2, Mary Hoekstra1,2, Hao Yu Chen1,2, Jian Rong4, Line Dufresne2, Jie Yao5, Xiuqing Guo5, Michael Y Tsai6, Sotirios Tsimikas7, Wendy S Post8, Ramachandran S Vasan4, Jerome I Rotter5, Martin G Larson4.   

Abstract

OBJECTIVE: Lp(a) (lipoprotein[a]) is an independent risk factor for cardiovascular diseases and plasma levels are primarily determined by variation at the LPA locus. We performed a genome-wide association study in the UK Biobank to determine whether additional loci influence Lp(a) levels. Approach and
Results: We included 293 274 White British individuals in the discovery analysis. Approximately 93 095 623 variants were tested for association with natural log-transformed Lp(a) levels using linear regression models adjusted for age, sex, genotype batch, and 20 principal components of genetic ancestry. After quality control, 131 independent variants were associated at genome-wide significance (P≤5×10-8). In addition to validating previous associations at LPA, APOE, and CETP, we identified a novel variant at the APOH locus, encoding β2GPI (beta2-glycoprotein I). The APOH variant rs8178824 was associated with increased Lp(a) levels (β [95% CI] [ln nmol/L], 0.064 [0.047-0.081]; P=2.8×10-13) and demonstrated a stronger effect after adjustment for variation at the LPA locus (β [95% CI] [ln nmol/L], 0.089 [0.076-0.10]; P=3.8×10-42). This association was replicated in a meta-analysis of 5465 European-ancestry individuals from the Framingham Offspring Study and Multi-Ethnic Study of Atherosclerosis (β [95% CI] [ln mg/dL], 0.16 [0.044-0.28]; P=0.0071).
CONCLUSIONS: In a large-scale genome-wide association study of Lp(a) levels, we identified APOH as a novel locus for Lp(a) in individuals of European ancestry. Additional studies are needed to determine the precise role of β2GPI in influencing Lp(a) levels as well as its potential as a therapeutic target.

Entities:  

Keywords:  atherosclerosis; cardiovascular diseases; genome-wide association study; lipoprotein(a); risk factors

Mesh:

Substances:

Year:  2020        PMID: 33115273      PMCID: PMC7769958          DOI: 10.1161/ATVBAHA.120.314965

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  46 in total

1.  A genome-wide association study on lipoprotein (a) levels and coronary artery disease severity in a Chinese population.

Authors:  Yibin Liu; Hongkun Ma; Qian Zhu; Bin Zhang; Hong Yan; Hanping Li; Jinxiu Meng; Weihua Lai; Liwen Li; Danqing Yu; Shilong Zhong
Journal:  J Lipid Res       Date:  2019-06-11       Impact factor: 5.922

Review 2.  Lipoprotein(a): resurrected by genetics.

Authors:  F Kronenberg; G Utermann
Journal:  J Intern Med       Date:  2012-11-12       Impact factor: 8.989

3.  Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype: An Analysis of 431 239 Patients.

Authors:  Patrick M Moriarty; Stephen A Varvel; Philip L S M Gordts; Joseph P McConnell; Sotirios Tsimikas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-01-05       Impact factor: 8.311

4.  Genetic variation in LPAL2, LPA, and PLG predicts plasma lipoprotein(a) level and carotid artery disease risk.

Authors:  James Ronald; Ramakrishnan Rajagopalan; Felecia Cerrato; Alex S Nord; Thomas Hatsukami; Ted Kohler; Santica Marcovina; Patrick Heagerty; Gail P Jarvik
Journal:  Stroke       Date:  2010-12-02       Impact factor: 7.914

5.  Identification of structural mutations in the fifth domain of apolipoprotein H (beta 2-glycoprotein I) which affect phospholipid binding.

Authors:  D K Sanghera; D R Wagenknecht; J A McIntyre; M I Kamboh
Journal:  Hum Mol Genet       Date:  1997-02       Impact factor: 6.150

6.  Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a).

Authors:  Gregor Leibundgut; Corey Scipione; Huiyong Yin; Matthias Schneider; Michael B Boffa; Simone Green; Xiaohong Yang; Edward Dennis; Joseph L Witztum; Marlys L Koschinsky; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2013-07-04       Impact factor: 5.922

7.  Safety of anacetrapib in patients with or at high risk for coronary heart disease.

Authors:  Christopher P Cannon; Sukrut Shah; Hayes M Dansky; Michael Davidson; Eliot A Brinton; Antonio M Gotto; Michael Stepanavage; Sherry Xueyu Liu; Patrice Gibbons; Tanya B Ashraf; Jennifer Zafarino; Yale Mitchel; Philip Barter
Journal:  N Engl J Med       Date:  2010-11-17       Impact factor: 91.245

Review 8.  Apolipoprotein E isoforms and lipoprotein metabolism.

Authors:  Michael C Phillips
Journal:  IUBMB Life       Date:  2014-09       Impact factor: 3.885

9.  Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients.

Authors:  M Rath; A Niendorf; T Reblin; M Dietel; H J Krebber; U Beisiegel
Journal:  Arteriosclerosis       Date:  1989 Sep-Oct

10.  Genome-wide significant results identified for plasma apolipoprotein H levels in middle-aged and older adults.

Authors:  Karen A Mather; Anbupalam Thalamuthu; Christopher Oldmeadow; Fei Song; Nicola J Armstrong; Anne Poljak; Elizabeth G Holliday; Mark McEvoy; John B Kwok; Amelia A Assareh; Simone Reppermund; Nicole A Kochan; Teresa Lee; David Ames; Margaret J Wright; Julian N Trollor; Peter W Schofield; Henry Brodaty; Rodney J Scott; Peter R Schofield; John R Attia; Perminder S Sachdev
Journal:  Sci Rep       Date:  2016-03-31       Impact factor: 4.379

View more
  9 in total

Review 1.  The Roles of Fatty Acids and Apolipoproteins in the Kidneys.

Authors:  Xiaoyue Pan
Journal:  Metabolites       Date:  2022-05-20

Review 2.  Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene.

Authors:  Stefan Coassin; Florian Kronenberg
Journal:  Atherosclerosis       Date:  2022-05       Impact factor: 6.847

Review 3.  Familial Hypercholesterolemia and Elevated Lipoprotein(a): Cascade Testing and Other Implications for Contextual Models of Care.

Authors:  Wann Jia Loh; Dick C Chan; Pedro Mata; Gerald F Watts
Journal:  Front Genet       Date:  2022-04-27       Impact factor: 4.772

Review 4.  Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study.

Authors:  David Šuran; Helena Blažun Vošner; Jernej Završnik; Peter Kokol; Andreja Sinkovič; Vojko Kanič; Marko Kokol; Franjo Naji; Tadej Završnik
Journal:  Front Public Health       Date:  2022-07-05

5.  Single-Cell Sequencing of Hepatocellular Carcinoma Reveals Cell Interactions and Cell Heterogeneity in the Microenvironment.

Authors:  Xinyao Li; Lei Wang; Liusong Wang; Zanjie Feng; Cijun Peng
Journal:  Int J Gen Med       Date:  2021-12-22

6.  Genome-Wide Characterization of a Highly Penetrant Form of Hyperlipoprotein(a)emia Associated With Genetically Elevated Cardiovascular Risk.

Authors:  Stefan Coassin; Kevin Chemello; Ilya Khantalin; Lukas Forer; Patricia Döttelmayer; Sebastian Schönherr; Rebecca Grüneis; Clément Chong-Hong-Fong; Brice Nativel; Stéphane Ramin-Mangata; Antonio Gallo; Mathias Roche; Beatrix Muelegger; Christian Gieger; Annette Peters; Johannes Zschocke; Catherine Marimoutou; Olivier Meilhac; Claudia Lamina; Florian Kronenberg; Valentin Blanchard; Gilles Lambert
Journal:  Circ Genom Precis Med       Date:  2022-02-08

7.  Machine Learning Prediction of Biomarkers from SNPs and of Disease Risk from Biomarkers in the UK Biobank.

Authors:  Erik Widen; Timothy G Raben; Louis Lello; Stephen D H Hsu
Journal:  Genes (Basel)       Date:  2021-06-29       Impact factor: 4.141

8.  Lipoprotein Proteomics and Aortic Valve Transcriptomics Identify Biological Pathways Linking Lipoprotein(a) Levels to Aortic Stenosis.

Authors:  Raphaëlle Bourgeois; Jérôme Bourgault; Audrey-Anne Despres; Nicolas Perrot; Jakie Guertin; Arnaud Girard; Patricia L Mitchell; Clarisse Gotti; Sylvie Bourassa; Corey A Scipione; Nathalie Gaudreault; Michael B Boffa; Marlys L Koschinsky; Philippe Pibarot; Arnaud Droit; Sébastien Thériault; Patrick Mathieu; Yohan Bossé; Benoit J Arsenault
Journal:  Metabolites       Date:  2021-07-16

Review 9.  Elevated Lipoprotein(a): Background, Current Insights and Future Potential Therapies.

Authors:  Ahmed Handhle; Adie Viljoen; Anthony S Wierzbicki
Journal:  Vasc Health Risk Manag       Date:  2021-09-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.